How to build a leading-practice RWE program to inform Market Access and value-based drug contracting

Current trends, and what to expect next, in the use of RWE to inform innovative contracting between pharma manufacturers and payers.

Real-life examples of how biopharma companies are using RWE to enable value-based care initiatives, including the stage of lifecycle where discussions begin.

How to build platform-based infrastructure and processes to enable these types of contracts; for instance, using rapid-cycle analytics™ to quickly and iteratively run analyses in a transparent manner that enables trust with U.S. payers.